PRO-ETHIC'S MIGRAINE DRUG MOVES TO PHASE III TRIAL

Pro-Ethic Pharmaceuticals has initiated its pivotal Phase III trial of its migraine product candidate, PRO-513. The study will involve 650 patients in 21 centers over the next eight months.

ProEthic obtained the exclusive U.S. and Canadian marketing rights for PRO-513 from a Swiss drug development company in 2005. The company expects the drug to go to market in early 2008.